title: Importance and management of dyslipidemia in the metabolic syndrome.
abstract: The metabolic syndrome is a common disorder characterized by central obesity, impaired glucose tolerance, hypertension, and atherogenic dyslipidemia (including the combination of hypertriglyceridemia, low levels of high-density lipoprotein cholesterol, and a preponderance of small, dense low-density lipoprotein particles). In this manuscript, we review the pathogenesis and significance of dyslipidemia in the metabolic syndrome, the role of nonpharmacologic therapy with therapeutic lifestyle changes, and drug therapies, including statins, fibrates, nicotinic acid, and omega-3 fatty acids or fish oils, alone or in drug combinations, to improve lipids and reduce the chance of subsequent cardiovascular disease events.
authors.affiliation: Department of Cardiovascular Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Menuet
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Lavie
authors.forename: Richard V
authors.initials: RV
authors.lastname: Milani
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000209:etiology / Q000473:pathology / Q000628:therapy; D004032:Diet; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005395:Fish Oils / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications / Q000473:pathology* / Q000628:therapy*; D008019:Life Style; D009765:Obesity / Q000150:complications / Q000473:pathology* / Q000628:therapy*; D013577:Syndrome
chemical_list: D000924:Anticholesteremic Agents; D004338:Drug Combinations; D005395:Fish Oils